Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston's Liberte bare-metal stent:

This article was originally published in Clinica

Executive Summary

Boston Scientific has received Japanese approval for its bare-metal stent, Liberte, which also serves as the platform for the firm's second-generation paclitaxel-eluting stent, Taxus Liberte. "The approval of our Liberte stent represents an important step in the evolution of our drug-eluting stent (DES) programme in Japan," said Paul LaViolette, Boston's COO. The firm's Taxus Liberte has been CE-marked for sale in Europe since September 2005, and it hopes to launch the DES in the US during 2007. The firm is not yet ready to speculate on when the DES is likely to penetrate the Japanese market, but claims that it can now look forward to long-awaited Japanese approval of its first-generation Taxus Express 2 stent in mid-2007. Boston claims that Liberte provides physicians with enhanced lesion access in challenging anatomy due to its thin struts and highly flexible cell design.

You may also be interested in...

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts